Command Palette

Search for a command to run...

Preprint WatchModerateAugust 28th, 2026

Nuclear exclusion of menin drives functional MEN1 deficiency in non-MEN1 prolactinomas: mouse models and human biopsies

Peña-Zanoni M, Flores-Martínez Á, Bornancini D, Abeledo Machado A, Segobia V, Rulli S, Luque R, Díaz-Torga G.

Menin is functionally deficient in sporadic prolactinomas through nuclear exclusion rather than loss of MEN1 transcription, with protein restricted to the cytoplasm in lactotrophs while pituitary Men1 mRNA stays unchanged.

Moderate contradiction

2 prior failures

Two documented clinical failures match this mechanism, or a single Phase 3 failure is on record.

This preprint reports that menin can be functionally lost by nuclear exclusion while MEN1 transcript levels stay flat, which uncouples menin protein abundance from menin function. Claidex holds two MEN1 failures. [[revumenib-men1-menin-colorectal-solid-tumors-phase1-2-efficacy-termination]] recorded an efficacy failure of a menin inhibitor in colorectal cancer and other solid tumours outside the leukaemia setting where the mechanism is validated, and [[icovamenib-t1d-covalent-112-portfolio-shutdown]] recorded a portfolio shutdown of a covalent menin inhibitor in type 1 diabetes. Both programmes assume that inhibiting the menin protein present in a cell translates into loss of menin-dependent transcription. A mechanism in which menin is already excluded from the nucleus predicts that expression-based patient selection would overstate the drug-addressable fraction. The flag is moderate because one of the two matching failures is an efficacy failure and because the claim bears directly on target engagement rather than on downstream pharmacology.

Abstract excerpt

ABSTRACT Prolactinomas, the most common secretory pituitary tumour subtype, frequently occur in patients with Multiple Endocrine Neoplasia type 1, caused by germline MEN1 mutations encoding menin. While menin loss is well established in MEN1-associated prolactinomas, its role in sporadic tumours remains unclear. We investigated menin expression, subcellular localization, and downstream signalling in two murine models of non-MEN1 prolactinomas, the dopamine D2-receptor knockout and the hCGβ-subunit-overexpressing mice, in which only females develop prolactinoma. Pituitary Men1 expression, analysed by qPCR, remained unchanged despite the genotype, in both sexes. However, in prolactinomas, lactotrophs exhibited a marked loss of nuclear MEN1 immunostained, with protein restricted to the cytoplasm. Male mice pituitaries retained nuclear MEN1 localization regardless their genotype. Loss of nuclear menin in prolactinomas was associated with reduced p27 and Pten expression, increased Ccnd1 expression, and enhanced pAKT. Moreover, by using in vivo pharmacological and surgical approaches we demonstrated that dopamine-agonist treatment preserved nuclear menin in lactotrophs, whereas dopamine blockade or estradiol induced its nuclear loss. Importantly, analysis of human pituitary biopsies confirmed nuclear and cytoplasmic menin localization in lactotrophs from normal pituitaries, and in prolactinomas from both genders following dopamine agonist therapy. However, in a prolactinoma from an untreated female, nuclear menin was partially lost. Therefore, our findings identify a state of functional MEN1-deficiency in sporadic prolactinomas (characterized by preserved MEN1 expression), but its exclusion from the nucleus (linked to activation of proliferative pathways, impaired tumour suppressor signalling, and tumour development) highlights the restoration of nuclear MEN1 localization as a potential therapeutic strategy. Graphical abstract Novel mechanism of functional MEN1 deficiency

Matching Claidex post-mortems

2 of 2 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.